Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Poliomyelitis Vaccine inactivated · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| Group 1 | EXPERIMENTAL | - |
| Group 2 | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Poliomyelitis Vaccine inactivated | BIOLOGICAL | 0.5 mL, Intramuscular |
| Poliomyelitis Vaccine in Dragee Candy (Human Diploid Cell) | BIOLOGICAL | 1g dragee, oral |
Inclusion Criteria: * Aged 2 months (60-70 days) on the day of inclusion into the study * Born at full term pregnancy ( over 36 weeks) with a birth weight ≥ 2.5 kg 2Ibs) or more * Parent(s) or legal representative able to understand and give authorization and sign informed consent for participation...
Poliomyelitis Vaccine inactivated is used for the prevention of poliomyelitis, a viral infection that can cause paralysis. It is an inactivated vaccine designed to protect against polio and is being studied for use in infants.
Sanofi (ticker: SNY) is the developer of Poliomyelitis Vaccine inactivated. The vaccine is being investigated for the prevention of poliomyelitis.
Poliomyelitis Vaccine inactivated is in Phase 3 clinical development. It is an investigational vaccine and has not been approved for use. The Phase 3 trial has been completed.
Poliomyelitis Vaccine inactivated has one completed Phase 3 trial, NCT00348387, which evaluated its immunogenicity and safety in Chinese infants compared to local oral polio vaccine. The trial enrolled 600 participants.
Yes, Poliomyelitis Vaccine inactivated is the same as Imovax Polio. The Phase 3 trial NCT00348387 specifically studied Imovax Polio in Chinese infants.